Intracellular metabolism of the antiherpes agent (S)-1-[3-hydroxy-2- (phosphonylmethoxy)propyl]cytosine

HT Ho, KL Woods, JJ Bronson, H De Boeck, JC Martin and MJ Hitchcock

Bristol-Myers Squibb Company, Wallingford, Connecticut 06492.

(S)-1-[3-Hydroxy-2-(phosphonylmethoxy)propyl]cytosine (HPMPC) is an antiviral phosphonate nucleotide analogue that displays activity against a range of herpesviruses. Anion exchange high performance liquid chromatography analysis of the 60% methanol extract from [14C]HPMPC-treated cells reveals the formation of three major metabolites. Two of these were identified as phosphorylated forms of HPMPC, HPMPC phosphate, and HPMPC diphosphate, by liberation of HPMPC upon acid digestion and coelution with synthetic standards on high performance liquid chromatography. The third metabolite, which is resistant to alkaline phosphatase cleavage but sensitive to phosphodiesterase, is proposed to be an HPMPC phosphate adduct. In herpes simplex virus-1-infected cells the same three metabolites are detected, at concentrations comparable to those in uninfected cells. When HPMPC is removed from the medium, the concentrations of the metabolites in cells decrease slowly, with half-lives of approximately 6, 17, and 48 hr for HPMPC phosphate, HPMPC diphosphate, and the HPMPC phosphate adduct, respectively. HPMPC diphosphate inhibits herpes simplex virus-1 and -2 DNA polymerases with a lower Ki than that for DNA polymerase alpha, and enzyme inhibition is competitive in each case. The formation and the persistence of HPMPC phosphates in cells and the selective inhibition of viral DNA polymerases by HPMPC diphosphate can explain why cells pretreated with HPMPC remain refractory to viral infection even long after HPMPC is removed from the medium.

Volume 41, Issue 1, pp. 197-202, 01/01/1992
Copyright © 1992 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				G. R. Painter, M. R. Almond, L. C. Trost, B. M. Lampert, J. Neyts, E. De Clercq, B. E. Korba, K. A. Aldern, J. R. Beadle, and K. Y. Hostetler Evaluation of Hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)Propyl]- Adenine, CMX157, as a Potential Treatment for Human Immunodeficiency Virus Type 1 and Hepatitis B Virus Infections Antimicrob. Agents Chemother., October 1, 2007; 51(10): 3505 - 3509. [Abstract] [Full Text] [PDF]

				S. Liekens, S. Gijsbers, E. Vanstreels, D. Daelemans, E. De Clercq, and S. Hatse The Nucleotide Analog Cidofovir Suppresses Basic Fibroblast Growth Factor (FGF2) Expression and Signaling and Induces Apoptosis in FGF2-Overexpressing Endothelial Cells Mol. Pharmacol., March 1, 2007; 71(3): 695 - 703. [Abstract] [Full Text] [PDF]

				T. Imaoka, H. Kusuhara, M. Adachi, J. D. Schuetz, K. Takeuchi, and Y. Sugiyama Functional Involvement of Multidrug Resistance-Associated Protein 4 (MRP4/ABCC4) in the Renal Elimination of the Antiviral Drugs Adefovir and Tenofovir Mol. Pharmacol., February 1, 2007; 71(2): 619 - 627. [Abstract] [Full Text] [PDF]

				E. G. Romanowski, K. A. Yates, B. Teuchner, M. Nagl, E. U. Irschick, and Y. J. Gordon N-Chlorotaurine Is an Effective Antiviral Agent against Adenovirus In Vitro and in the Ad5/NZW Rabbit Ocular Model Invest. Ophthalmol. Vis. Sci., May 1, 2006; 47(5): 2021 - 2026. [Abstract] [Full Text] [PDF]

				P. Randhawa, N. A. Farasati, R. Shapiro, and K. Y. Hostetler Ether Lipid Ester Derivatives of Cidofovir Inhibit Polyomavirus BK Replication In Vitro. Antimicrob. Agents Chemother., April 1, 2006; 50(4): 1564 - 1566. [Abstract] [Full Text] [PDF]

				W. Zhu, A. Burnette, D. Dorjsuren, P. E. Roberts, M. Huleihel, R. H. Shoemaker, V. E. Marquez, R. Agbaria, and S. Sei Potent Antiviral Activity of North-Methanocarbathymidine against Kaposi's Sarcoma-Associated Herpesvirus Antimicrob. Agents Chemother., December 1, 2005; 49(12): 4965 - 4973. [Abstract] [Full Text] [PDF]

				W. C. Magee, K. Y. Hostetler, and D. H. Evans Mechanism of Inhibition of Vaccinia Virus DNA Polymerase by Cidofovir Diphosphate Antimicrob. Agents Chemother., August 1, 2005; 49(8): 3153 - 3162. [Abstract] [Full Text] [PDF]

				M. Bray and C. J. Roy Antiviral prophylaxis of smallpox J. Antimicrob. Chemother., July 1, 2004; 54(1): 1 - 5. [Abstract] [Full Text] [PDF]

				E. De Clercq Clinical Potential of the Acyclic Nucleoside Phosphonates Cidofovir, Adefovir, and Tenofovir in Treatment of DNA Virus and Retrovirus Infections Clin. Microbiol. Rev., October 1, 2003; 16(4): 569 - 596. [Abstract] [Full Text] [PDF]

				C. J. Roy, R. Baker, K. Washburn, and M. Bray Aerosolized Cidofovir Is Retained in the Respiratory Tract and Protects Mice against Intranasal Cowpox Virus Challenge Antimicrob. Agents Chemother., September 1, 2003; 47(9): 2933 - 2937. [Abstract] [Full Text] [PDF]

				K. A. Aldern, S. L. Ciesla, K. L. Winegarden, and K. Y. Hostetler Increased Antiviral Activity of 1-O-Hexadecyloxypropyl-[2-14C]cidofovir in MRC-5 Human Lung Fibroblasts Is Explained by Unique Cellular Uptake and Metabolism Mol. Pharmacol., March 1, 2003; 63(3): 678 - 681. [Abstract] [Full Text] [PDF]

				D. L. Wolf, C. A. Rodriguez, M. Mucci, A. Ingrosso, B. A. Duncan, and D. J. Nickens Pharmacokinetics and Renal Effects of Cidofovir with a Reduced Dose of Probenecid in HIV-Infected Patients with Cytomegalovirus Retinitis J. Clin. Pharmacol., January 1, 2003; 43(1): 43 - 51. [Abstract] [Full Text]

				P. M. Krosky, K. Z. Borysko, M. R. Nassiri, R. V. Devivar, R. G. Ptak, M. G. Davis, K. K. Biron, L. B. Townsend, and J. C. Drach Phosphorylation of {beta}-D-Ribosylbenzimidazoles Is Not Required for Activity against Human Cytomegalovirus Antimicrob. Agents Chemother., February 1, 2002; 46(2): 478 - 486. [Abstract] [Full Text] [PDF]

				I. Buerger, J. Reefschlaeger, W. Bender, P. Eckenberg, A. Popp, O. Weber, S. Graeper, H.-D. Klenk, H. Ruebsamen-Waigmann, and S. Hallenberger A Novel Nonnucleoside Inhibitor Specifically Targets Cytomegalovirus DNA Maturation via the UL89 and UL56 Gene Products J. Virol., October 1, 2001; 75(19): 9077 - 9086. [Abstract] [Full Text] [PDF]

				J. C. Lenzo, G. R. Shellam, and C. M. Lawson Ganciclovir and Cidofovir Treatment of Cytomegalovirus-Induced Myocarditis in Mice Antimicrob. Agents Chemother., May 1, 2001; 45(5): 1444 - 1449. [Abstract] [Full Text]

				E. De Clercq Vaccinia Virus Inhibitors as a Paradigm for the Chemotherapy of Poxvirus Infections Clin. Microbiol. Rev., April 1, 2001; 14(2): 382 - 397. [Abstract] [Full Text] [PDF]

				D. R. Dancey, D. W. Chamberlain, M. Krajden, J. Palefsky, P.W. Alberti, and G. P. Downey Successful Treatment of Juvenile Laryngeal Papillomatosis-Related Multicystic Lung Disease With Cidofovir Case Report and Review of the Literature Chest, October 1, 2000; 118(4): 1210 - 1214. [Abstract] [Full Text] [PDF]

				S. M. Pransky, D. F. Brewster, A. E. Magit, and D. B. Kearns Clinical Update on 10 Children Treated With Intralesional Cidofovir Injections for Severe Recurrent Respiratory Papillomatosis Arch Otolaryngol Head Neck Surg, October 1, 2000; 126(10): 1239 - 1243. [Abstract] [Full Text] [PDF]

				J. R. Toro, L. V. Wood, N. K. Patel, and M. L. Turner Topical Cidofovir: A Novel Treatment for Recalcitrant Molluscum Contagiosum in Children Infected With Human Immunodeficiency Virus 1 Arch Dermatol, August 1, 2000; 136(8): 983 - 985. [Full Text] [PDF]

				R. T. Sarisky, T. T. Nguyen, K. E. Duffy, R. J. Wittrock, and J. J. Leary Difference in Incidence of Spontaneous Mutations between Herpes Simplex Virus Types 1 and 2 Antimicrob. Agents Chemother., June 1, 2000; 44(6): 1524 - 1529. [Abstract] [Full Text]

				U R Hengge and G Tietze Successful treatment of recalcitrant condyloma with topical cidofovir Sex. Transm. Inf., April 1, 2000; 76(2): 143 - 143. [Full Text] [PDF]

				G. Andrei, R. Snoeck, E. De Clercq, R. Esnouf, P. Fiten, and G. Opdenakker Resistance of herpes simplex virus type 1 against different phosphonylmethoxyalkyl derivatives of purines and pyrimidines due to specific mutations in the viral DNA polymerase gene J. Gen. Virol., March 1, 2000; 81(3): 639 - 648. [Abstract] [Full Text]

				E. S. HO, D. C. LIN, D. B. MENDEL, and T. CIHLAR Cytotoxicity of Antiviral Nucleotides Adefovir and Cidofovir Is Induced by the Expression of Human Renal Organic Anion Transporter 1 J. Am. Soc. Nephrol., March 1, 2000; 11(3): 383 - 393. [Abstract] [Full Text] [PDF]

				J. Bedard, S. May, M. Lis, L. Tryphonas, J. Drach, J. Huffman, R. Sidwell, L. Chan, T. Bowlin, and R. Rando Comparative Study of the Anti-Human Cytomegalovirus Activities and Toxicities of a Tetrahydrofuran Phosphonate Analogue of Guanosine and Cidofovir Antimicrob. Agents Chemother., March 1, 1999; 43(3): 557 - 567. [Abstract] [Full Text]

				P. M. Krosky, M. R. Underwood, S. R. Turk, K. W.-H. Feng, R. K. Jain, R. G. Ptak, A. C. Westerman, K. K. Biron, L. B. Townsend, and J. C. Drach Resistance of Human Cytomegalovirus to Benzimidazole Ribonucleosides Maps to Two Open Reading Frames: UL89 and UL56 J. Virol., June 1, 1998; 72(6): 4721 - 4728. [Abstract] [Full Text] [PDF]

				M. A. Jacobson Treatment of Cytomegalovirus Retinitis in Patients with the Acquired Immunodeficiency Syndrome N. Engl. J. Med., July 10, 1997; 337(2): 105 - 114. [Full Text] [PDF]

				V. M. Pisarev, S.-H. Lee, M. C. Connelly, and A. Fridland Intracellular Metabolism and Action of Acyclic Nucleoside Phosphonates on DNA Replication Mol. Pharmacol., July 1, 1997; 52(1): 63 - 68. [Abstract] [Full Text]

				C. S. Crumpacker Ganciclovir N. Engl. J. Med., September 5, 1996; 335(10): 721 - 729. [Full Text] [PDF]

				C.-C. Tsai, K. E. Follis, A. Sabo, T. W. Beck, R. F. Grant, N. Bischofberger, R. E. Benveniste, and R. Black Prevention of SIV Infection in Macaques by (R)-9-(2-Phosphonylmethoxypropyl)adenine Science, November 17, 1995; 270(5239): 1197 - 1199. [Abstract] [PDF]